# Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma

> **NCT02293109** · PHASE1 · COMPLETED · sponsor: **Mehrdad Abedi, MD** · enrollment: 10 (actual)

## Conditions studied

- Contiguous Stage II Adult Lymphoblastic Lymphoma
- Noncontiguous Stage II Adult Lymphoblastic Lymphoma
- Stage I Adult Lymphoblastic Lymphoma
- Stage III Adult Lymphoblastic Lymphoma
- Stage IV Adult Lymphoblastic Lymphoma
- Untreated Adult Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** carfilzomib
- **DRUG:** cyclophosphamide
- **DRUG:** vincristine sulfate
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** dexamethasone
- **DRUG:** methotrexate
- **DRUG:** cytarabine
- **DRUG:** leucovorin calcium
- **DRUG:** methylprednisolone
- **BIOLOGICAL:** rituximab
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT02293109
- **Lead sponsor:** Mehrdad Abedi, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-17
- **Primary completion:** 2017-12-13
- **Final completion:** 2018-01-11
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2022-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02293109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02293109, "Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02293109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*